1. Scrip
  2. >>R&D

BioAsia 2023: Focus Research Outside US, Take ‘One Health’ Approach To Prevent Next Pandemic

 
• By Vibha Ravi

Speakers from BMS, Takeda, UNICEF and more discussed how a shift in R&D focus, free flow of data on animal and human health, public sector investment and higher regulatory flexibility are key to make ‘One Health’ work and prevent future pandemics

BioAsia 2023 Panel On One Health Approach
BioAsia Panel Participants (Seated L to R) - Sai D Prasad (Bharat Biotech), Mahender Nayak (Takeda), V K Paul (NITI Aayog), Cynthia McCaffrey (UNICEF), Samit Hirawat (Bristol Myers), Richard Hatchett (CEPI). Moderator Gagandeep Kang (CMC) On Screen • Source: Scrip Norstella

“COVID-19 is gone, long live COVID” – this is not a proverb, thankfully so. But it could be, given that the global pharma industry is still drawing lessons from the pandemic caused by SARS-CoV-2 to prepare for the next one, which many in the scientific community say is inevitable.

A panel of officials from companies, regulators and multilateral organizations came together with scientists at a recent conference to consider how the ‘One Health’ methodology

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows more promise in slowing idiopathic pulmonary fibrosis.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

More from Scrip

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 
• By Dexter Jie Yan

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.

CRISPR Thinks Outside Gene-Editing Box With Sirius Deal

 
• By Alaric DeArment

The gene-editing company is making a deal with RNA interference-focused Sirius, but still focusing on cardiovascular disease, a major area of its pipeline.